ITM_Logo_Claim_RGB_high-res.png
ITM Obtains Manufacturing License in the U.S.
February 01, 2024 07:00 ET | ITM Isotope Technologies Munich SE
License will support ITM’s efforts in preparing for the commercialization of its diagnostic and therapeutic radiopharmaceutical pipeline across the U.S. Garching / Munich and...
ITM_Logo_Claim_RGB_high-res.png
ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program
January 30, 2024 07:00 ET | ITM Isotope Technologies Munich SE
GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9),...
Dr. Mark Harfensteller
ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board
January 16, 2024 05:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, Germany, January 16, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Mark Harfensteller to its...
ITM_Logo_Claim_RGB_high-res.png
ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site
January 04, 2024 07:54 ET | ITM Isotope Technologies Munich SE
Receipt of Radioactive Material Handling License (RAM License) for production of n.c.a. Lutetium-177Progress demonstrates company’s ability to rapidly increase GMP manufacturing capabilities to...
ITM_Logo_Claim_RGB_high-res.png
ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023 08:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, Germany, December 21, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster and CFO, Dr. Klaus...
ITM_Logo_Claim_RGB_high-res.png
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
December 14, 2023 09:28 ET | ITM Isotope Technologies Munich SE
ITM secures first-in-class folate precursors for radiolabeling to advance clinical and commercial development of its folate-based pipeline candidatesLicensing agreement broadens indication areas to...
ITM_Logo_Claim_RGB_high-res.png
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
December 14, 2023 09:26 ET | ITM Isotope Technologies Munich SE
  ITM secures first-in-class folate precursors for radiolabeling to advance clinical and commercial development of its folate-based pipeline candidatesLicensing agreement broadens...
ITM_Logo_Claim_RGB_high-res.png
ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics
October 24, 2023 08:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, Germany, October 24, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today reported on its participation at the 3rd International...
Actineer_Signing_Joe McBrearty_CEO of CNL_and_Steffen Schuster_CEO of ITM
ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225
October 18, 2023 08:00 ET | ITM Isotope Technologies Munich SE
  New company will advance Actinium-225 technologies, quickly secure supply, and construct a new production facility in Canada to produce industrial-scale quantities of rare medical isotope ...
ITM_Logo_Claim_RGB_high-res.png
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
July 31, 2023 09:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, Germany and Indianapolis, IN, USA, July 31, 2023 –  ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc. (NASDAQ:...